Journal
WORLD NEUROSURGERY
Volume 116, Issue -, Pages 518-528Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.wneu.2018.04.020
Keywords
CTLA-4; Glioblastoma; Immunotherapy; PD-1; PD-L1; Temozolomide
Categories
Ask authors/readers for more resources
Glioblastoma evades conventional therapies through a variety of mechanisms, including suppression of the immune system. This immunosuppressive microenvironment provides a potential target for treatment. There are several immunotherapies being actively investigated, including inhibition of immune checkpoint regulators, development of antitumor vaccinations from both dendritic cell and tumor peptide components, adoptive transfer of supercharged and durable T lymphocytes, and generation of oncolytic viruses. Although immunotherapy has already demonstrated efficacy for a variety of other malignancies, its efficacy in glioblastoma is still unclear. Identifying predictive biomarkers and improving the management of immune-related adverse effects will help to realize the full potential of these therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available